Pfizer and MIT are looking for more efficient biologics manufacturing

Biologic drugs are becoming a growing part of drugmakers' portfolios. But the complex molecules they are made of are difficult, and therefore expensive, to manufacture. Pfizer ($PFE) is partnering with the Massachusetts Institute of Technology (MIT) to see if they can find new processes that will cut costs and increase efficiency, the Boston Business Journal reports. The collaboration will include innovative technologies that the partners hope will allow them to use more genes in the process. Story